Stepan Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.73 M
as on 16-11-2024
- Company Age 36 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 16-11-2024
- Revenue -50.71%
(FY 2023)
- Profit -73.87%
(FY 2023)
- Ebitda -23.02%
(FY 2023)
- Net Worth 1.99%
(FY 2023)
- Total Assets -11.01%
(FY 2023)
About Stepan Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.73 M.
The company currently has active open charges totaling ₹1.50 M.
Shri Krishan, Gaurav Agrawal, and Charu Agrawal serve as directors at the Company.
- CIN/LLPIN
U74899DL1988PTC031908
- Company No.
031908
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 1988
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationNew Delhi, Delhi
- Telephone
- Email Address
- Website
- Social Media
What products or services does Stepan Laboratories Private Limited offer?
Stepan Laboratories Private Limited offers a wide range of products and services, including Nutraceuticals.
Who are the key members and board of directors at Stepan Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shri Krishan  | Director | 01-Jun-1988 | Current |
| Gaurav Agrawal | Director | 14-Mar-2007 | Current |
| Charu Agrawal | Additional Director | 15-Apr-2019 | Current |
Financial Performance of Stepan Laboratories.
Stepan Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 50.71% decrease. The company also saw a substantial fall in profitability, with a 73.87% decrease in profit. The company's net worth moved up by a moderate rise of 1.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stepan Laboratories?
In 2023, Stepan Laboratories had a promoter holding of 87.91% and a public holding of 12.09%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stepan Lifesciences Private LimitedActive 4 years 1 monthShri Krishan, Gaurav Agrawal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Apr 2019 | ₹1.50 M | Open |
How Many Employees Work at Stepan Laboratories?
Unlock and access historical data on people associated with Stepan Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stepan Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stepan Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
